Clinical trials for Small intestine and appendix cancer

36 currently recruiting clinical trials
Phase 3 Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Small intestine and appendix cancer #NCT07087054 #2024-519875-24-00
Ileum cancer Neuroendocrine tumor None
6 recruiting sites
Crinetics Pharmaceuticals Inc.
Phase 3 Small intestine and appendix cancer #NCT06878664 #2024-517921-14-00
Jejunum cancer Ileum cancer Neuroendocrine tumor Locally Advanced Metastatic None 1 SSTR Positive
Radiotherapy
1 recruiting site
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT03175224 #2024-514542-37-00
Locally Advanced Metastatic MET 1 2 3 or more
BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ALK ROS-1 Systemic Treatment-Naive Targeted therapy
5 recruiting sites
Apollomics
Phase 2 Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Sarcoma and GIST Small intestine and appendix cancer #NCT06333314 #2023-505298-34-00
Stomach Oesogastric junction Soft tissue sarcoma Adenocarcinoma Ampullary carcinoma Locally Advanced Metastatic MSI/dMMR None Systemic Treatment-Naive CPS Negative (< 1) CPS Positive (1 <= X < 5)
Immunotherapy Radiotherapy
6 recruiting sites
UNICANCER
Phase 2 Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06333314 #2023-505298-34-00
Neuroendocrine carcinoma MSI/dMMR None Systemic Treatment-Naive
Immunotherapy Radiotherapy
6 recruiting sites
UNICANCER
Phase 2 Small intestine and appendix cancer #NCT06278545 #2023-505486-92-00
Duodenum cancer Jejunum cancer Ileum cancer Adenocarcinoma Locally Advanced Metastatic None Systemic Treatment-Naive
MSI/dMMR
1 recruiting site
Centre Hospitalier Universitaire Dijon
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT05875168 #2023-507937-14-00
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
6 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2 Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT05592626 #2023-505334-10-00
Locally Advanced Metastatic MSI/dMMR 1 2 3 or more
Systemic Treatment-Naive
5 recruiting sites
Marengo Therapeutics, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06128551
Phase 1b extension de dose et phase 2 cohortes tumeurs solides naïves d'inhibiteurs de KRAS G12C
Locally Advanced Metastatic Metastatic Castration-resistant KRAS G12C 1 2 3 or more
Systemic Treatment-Naive Targeted therapy
7 recruiting sites
Revolution Medicines, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06128551
Phase 1b Escalade de dose
Locally Advanced Metastatic Metastatic Castration-resistant KRAS G12C 1 2 3 or more
Systemic Treatment-Naive
7 recruiting sites
Revolution Medicines, Inc.